Search This Blog

Monday, September 28, 2026

Kodiak Sciences' Phase 3 wet AMD trial meets primary endpoints for Zenkuda and tabirafusp-ted

 

Kodiak Sciences' Phase 3 DAYBREAK wet AMD trial meets primary endpoints for Zenkuda and tabirafusp-ted

  • Zenkuda showed strong efficacy, with a majority of patients maintained on a 24-week dosing interval under strict treat-to-dryness criteria.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)